MAIN CONTENT
The larger the benefit, the greater the need for trustworthy information
Semaglutide, used in Novo Nordisk’s Ozempic and Wegovy, mimics a natural GLP-1 hormone involved in blood-sugar regulation and satiety. Eli Lilly’s tirzepatide, sold as Mounjaro and Zepbound, acts on both GLP-1 and GIP pathways. These therapies have delivered meaningful benefits for many people facing metabolic disease. They are not identical products, however, and their approved uses, doses and safety profiles must not be treated as interchangeable.
The Washington Post described Todd Engel, a Maryland man who lost vision in both eyes after he began Ozempic. He is among patients suing pharmaceutical companies over allegedly inadequate warnings. His experience deserves attention, but the timing of an illness and a prescription alone cannot establish that the drug caused the injury. Novo Nordisk disputes the lawsuits and defends semaglutide’s safety profile; Lilly says it reviews emerging safety signals with regulators.
Vision loss: an exceptionally uncommon risk with serious consequences
NAION involves reduced blood flow to the optic nerve and can cause abrupt, often painless loss of sight. The FDA’s November 9 communication cited an analysis of 126 randomized trials: 6.4 NAION cases per 100,000 person-years among GLP-1 users versus 3.8 in comparator groups.

















